WVE WAVE Life Sciences

WAVE Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences:

  • Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation

    Wednesday, June 7th at 1:30 P.M. ET – New York
  • The JMP Securities Life Science Conference – Company Panel Discussion: Neuromuscular Disorders

    Tuesday, June 20th at 2:00 P.M. ET – New York

A live webcast of the WAVE company presentation at the Jefferies 2017 Global Healthcare Conference will be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. A replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Wave Life Sciences Ltd: 1 director

A director at Wave Life Sciences Ltd bought 8,772,496 shares at 6.227USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

Yun Zhong
  • Yun Zhong

We Still See Hope In WVE-007 Although Maybe Not As Mono; PT To $15; Re...

Clinical Data Suggest Combination with GLP-1 Therapy Leads to Higher Weight and Fat Reduction Than GLP-1 Alone. ARWR has reported data of combination of INHBE knockdown and a GLP-1 therapy from obese patients with type 2 diabetes (T2D). The combo leads to doubling of weight loss at 16 weeks and tri

ResearchPool Subscriptions

Get the most out of your insights

Get in touch